FOXO4-DRI is not approved by the U.S
Thus, we have demonstrated that GSH-targeted therapy selectively kills PC cells in an oxidative stress-dependent manner and that the differences in basal ROS level and antioxidant scavenging capacity induced by stratified expression of VRK2 can well account for the heterogeneous sensitivity to GSH inhibition
This distinction is important because endoscopic therapy may be considered for T1a disease, given the low risk of metastatic lymphadenopathy (2%) compared with submucosal disease, for which the risk of metastatic lymphadenopathy is 20% to 30%, and the therapy of choice is esophagectomy (which allows lymph node dissection and removal) in operative candidates
Deluca EV, Deluca EV, Perino F, Distefani A, Coco V, Fossati B, et al
Although these studies primarily focus on safety and tolerability, they also provide the first human data on pharmacokinetics and, early pharmacodynamic (biomarker)effects
doi: 10.1016/j.abb.2003.12.034